Figures
Abstract
Most patients with hepatitis C are treated with pangenotypic direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. GPs experienced in the management of hepatitis C can prescribe DAAs independently. Others must consult with a specialist before prescribing; online resources can streamline this process. Important considerations before prescribing include barriers to adherence and drug interactions.
Key Points
- Most people with hepatitis C can be treated with direct-acting antiviral (DAA) therapy in primary care.
- Pangenotypic DAA regimens that are well tolerated and effective against all hepatitis C genotypes include sofosbuvir/velpatasvir and glecaprevir/pibrentasvir.
- GPs who are experienced in the management of hepatitis C can prescribe DAAs independently, whereas others must consult with a specialist by phone, fax or email before DAA prescribing; online resources are available to facilitate this process.
- Considerations before prescribing DAAs include barriers to adherence and interactions between DAAs and prescribed medications and other drugs the patient takes.
- Clinical support, tools and resources to help GPs treat hepatitis C are available online.
